Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia

Bacigalupo, Andrea; Dominietto, Alida; Pozzi, Sarah; Miglino, Maurizio; Albarracin, Flavio; Piaggio, Giovanna; Bertolotti, Francesca.
Rev. bras. hematol. hemoter ; 30(supl.2): 42-44, jun. 2008.
Artículo en Inglés | LILACS | ID: lil-496444

Documentos relacionados

  1. Ponatinib-Related Vasospastic Angina.
  2. Monitoring of childhood ALL using <i>BCR-ABL1</i> genomic breakpoints identifies a subgroup with CML-like biology.
  3. Jak2/STAT6/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused by P190<sup>BCR-ABL</sup>.
  4. Red Blood Cell Deformability and Distribution Width in Patients with Hematologic Neoplasms.
  5. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
  6. Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China.
  7. Therapeutic Leukapheresis in Pediatric Leukemia: Utilization Trend and Early Outcomes in a US Nationwide Cohort.
  8. Total marrow lymphoid irradiation and cyclophosphamide is associated with low toxicity and good outcomes in patients undergoing hematopoietic stem cell transplantation for acute lymphoblastic leukemia and chronic myeloid leukemia in lymphoid blast crises - A phase I study.
  9. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
  10. Pediatric Chronic Myelogenous Leukemia in T-lineage Blast Crisis: A Reminder in Relevance.